ARTICLE | Clinical News

Eleven forges ahead in allergic conjunctivitis

August 13, 2015 1:46 AM UTC

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) gained $1.75 (75%) to $4.09 on Wednesday, giving it a market cap of $79.2 million, after it started a Phase III trial of EBI-005 to treat moderate to severe allergic conjunctivitis. Eleven expects top-line data from the study in 1Q16 and intends to start a second Phase III study in 2H16, pending results of the first trial.

CEO Abbie Celniker told BioCentury the vehicle-controlled trial will measure patient-reported ocular itching on a scale ranging from no itching to incapacitating itching. ...